Trying To Quit Smoking? This Show Is For You
Nothing’s quite as easy as becoming a smoker. A large part of that is because of the denial. You convince yourself you’re not a smoker if you just have a cigarette occasionally. You’re totally in control, you could stop whenever you want, you tell your friends and yourself. Only when you decide to stop, do you realize that there are few things more difficult than trying to quit smoking. Even after years of struggle and abstaining, it takes just a second for it all to go up in a puff. Literally. Many just give up trying because it all seems so hopeless.
Nicotex decided to ignite a spark of hope with their #ICanYouCan campaign. They encouraged and supported smokers trying to quit by starting online discussions and conversations about quitting, got celebrities who have quit smoking to speak up about their struggle, asked quitters to come forward and share their stories. Those trying to quit could finally see that others too have struggled for years till they finally overcome their personal Everest.
It didn’t stop there. Nicotex took the 6 most inspiring stories and gave those quitters a chance to climb Mount Everest. That’s the unique premise of the Nicotex ‘I Can You Can’ show that launches this Sunday on National Geographic Channel and Viu. On this 6-episode show, 6 participants will try to climb Mount Everest, while trying to conquer their personal uphill goal of quitting smoking. Out of the 6, three have already quit smoking, while the other three are trying to stop. ‘I Can You Can’ is hosted by Milind Soman, who himself quit smoking a long time ago.
This pack of quitters will start their journey from Kathmandu, make their way to the Everest Base Camp and from there climb up to Kala Patthar. It’s an arduous expedition but climbing Everest is not just about the destination, it’s about the mindset. It’s a lot like quitting smoking, you don’t know if you’ll succeed or if you’ll give up half-way. Only those who give it their all can conquer it, but when they do, they go on to become an inspiration to others. Watch a sneak preview of the show below.
Will this bunch of quitters be able to make it? Tune-in to National Geographic Channel at 7pm this Sunday or log on to Viu to watch their inspiring journey.
This article originally appeared on The Quint
Read it now
We wish you a very happy 72nd Indian Independence Day!
Seven decades after our historic tryst with destiny, on 15 August 2018, India will celebrate 72 years of independence, democracy and sovereignty. Presenting some interesting snippets from the archives on this occasion.
“India was officially proclaimed independent on 15th August 1947 with much celebrations in Delhi and other towns. Cipla celebrated the first Independence Day by a flag hoisting ceremony where all workers and staff of Cipla were present.”
– Dr. Khwaja Abdul Hamied,
‘A Life To Remember – An Autobiography’ (1972)
This is how India’s first Independence Day was celebrated by Cipla. The tricoloured Indian national flag was proudly unfurled and hoisted and the venue was Cipla’s very first manufacturing site and headquarters in Mumbai Central.
Cipla’s celebration of Indian independence did not end there. As a nationalist and freedom fighter, Dr. K.A. Hamied ensured that Cipla as an employer played its part in making the occasion unforgettable for Ciplaites by announcing a generous Independence Bonus!
The late Dr. A.R. Kidwai was a multi-faceted personality – public servant, scholar, statesman extraordinaire of post-independence India. Dr. Kidwai was a Cipla chemist from 1941 to 1945 and was witness to early scientific projects of Cipla as well as the involvement of then Ciplaites in the independence movement. Here’s a snippet of his reflections from the Oral History collection of the archives.
This advertisement placed by Cipla in the 1948 edition of the journal, Marg is a strong reminder of how Cipla was a trail-blazer in pharma R&D, quality and manufacturing in India, and saw itself as second to none. Spend a minute or two to read it with its context in mind – a time of euphoria, great promise, unrealised potential. A time when the state of India would finally attain equality in status with others on the world stage. Cipla’s strides were a microcosm of India’s in so many ways.
On that note, we wish you a very happy 72nd Indian Independence Day!
Cipla Receives Final Approval for Generic Reyataz® (Atazanavir Caps 100mg, 150mg, 200mg, 300mg)
Cipla Limited (“Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Atazanavir Caps 100mg, 150mg, 200mg, 300mg from the United States Food
and Drug Administration (US FDA).
Cipla’s Atazanavir Caps 100mg, 150mg, 200mg, 300mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Reyataz®. It is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of 6 years and older weighing at least 15 kg.
According to IQVIA (IMS Health), Reyataz® and its generic equivalents had US sales of approximately $324M for the 12-month period ending April 2018.
Cipla partners with MSN Laboratories for marketing and distribution of generic Xeloda® (Capecitabine Tabs 150mg and 500mg)
Cipla USA, Inc., (“Cipla”) a subsidiary of Cipla Limited, today announced that it has secured rights from MSN Laboratories Private Limited to market & distribute Capecitabine 150mg and 500mg tablets in the United States of America. The product is available immediately.
The Capecitabine 150mg and 500mg tablet is an AB-rated generic therapeutic equivalent version of Genentech’s Xeloda®. Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
As per IQVIA (IMS Health), Xeloda® and its generic equivalents had sales of approximately $178M for the 12-month period ending June 2018 in the United States.
About MSN Group
Founded in 2003 with a mission to make health care affordable, the MSN Group based out of Hyderabad is one of the fastest growing research-based pharmaceutical company in India. MSN has 10 API (including Oncology) and
five finished dosage facilities out of which three in Hyderabad, one both in USA & Myanmar. MSN Labs has an integrated R&D Center for both API and product formulation under one roof. The company’s core strategy will be to focus on high barrier of entry & first to market paragraph 4 products. MSN customer base exceeds 250 customers with a global presence in 65 countries throughout US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. With more than 350 National & International patents filed, MSN’s product basket offers 300 APIs & 200 Formulations covering 35 major therapies.
Cipla Receives USFDA Approval for Generic Voltaren® Gel (Diclofenac Sodium Topical Gel, 1%)
Cipla Limited (“Cipla”) announced that it has received final approval on August 3, 2018, for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the United States Food and Drug Administration (US FDA).
Cipla’s Diclofenac Sodium Topical Gel, 1% is AB-rated generic therapeutic equivalent to the reference listed drug (RLD), Voltaren® Gel, 1% of GlaxoSmithKline Consumer Health®. It is a non-steroidal anti-inflammatory drug
indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands.
According to IQVIA (IMS Health), Voltaren® Gel and its generic equivalents had US sales of approximately $353M for the 12-month period ending June 2018. The product will be available for shipping in the US in the upcoming week.